Matthew Jenner

5.0k total citations
86 papers, 1.8k citations indexed

About

Matthew Jenner is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Matthew Jenner has authored 86 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Hematology, 60 papers in Molecular Biology and 44 papers in Oncology. Recurrent topics in Matthew Jenner's work include Multiple Myeloma Research and Treatments (79 papers), Protein Degradation and Inhibitors (43 papers) and Peptidase Inhibition and Analysis (24 papers). Matthew Jenner is often cited by papers focused on Multiple Myeloma Research and Treatments (79 papers), Protein Degradation and Inhibitors (43 papers) and Peptidase Inhibition and Analysis (24 papers). Matthew Jenner collaborates with scholars based in United Kingdom, United States and Italy. Matthew Jenner's co-authors include Gareth J. Morgan, Faith E. Davies, Brian A. Walker, Fiona M. Ross, Paola Leone, David González, Walter M. Gregory, Nicholas J. Dickens, David C. Johnson and Kevin Boyd and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Matthew Jenner

80 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Jenner United Kingdom	23	1.4k	1.3k	755	200	120	86	1.8k
Annamaria Brioli Italy	20	1.8k 1.3×	1.3k 1.0×	954 1.3×	255 1.3×	167 1.4×	72	2.2k
Dixie‐Lee Esseltine United States	11	1.1k 0.8×	1.2k 0.9×	817 1.1×	285 1.4×	190 1.6×	12	1.8k
Sharianne G. Louie United States	11	859 0.6×	1.0k 0.8×	581 0.8×	403 2.0×	119 1.0×	12	2.0k
Sarah Waheed United States	22	1.7k 1.2×	1.4k 1.1×	935 1.2×	219 1.1×	162 1.4×	69	2.0k
Firas Muwalla United States	11	1.2k 0.9×	970 0.8×	556 0.7×	190 0.9×	80 0.7×	13	1.4k
Oliver Galm Germany	23	602 0.4×	1.5k 1.2×	436 0.6×	231 1.2×	142 1.2×	51	2.0k
Jan B. Egan United States	16	709 0.5×	868 0.7×	448 0.6×	216 1.1×	436 3.6×	34	1.6k
D Bracy United States	14	1.5k 1.1×	874 0.7×	692 0.9×	204 1.0×	91 0.8×	17	1.6k
Sören Lehmann Sweden	27	1.2k 0.9×	1.2k 0.9×	667 0.9×	507 2.5×	131 1.1×	77	2.3k
Owen Stephens United States	13	541 0.4×	780 0.6×	515 0.7×	63 0.3×	109 0.9×	31	1.2k

Countries citing papers authored by Matthew Jenner

Since Specialization

Citations

This map shows the geographic impact of Matthew Jenner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Jenner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Jenner more than expected).

Fields of papers citing papers by Matthew Jenner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Jenner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Jenner. The network helps show where Matthew Jenner may publish in the future.

Co-authorship network of co-authors of Matthew Jenner

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Jenner. A scholar is included among the top collaborators of Matthew Jenner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Jenner. Matthew Jenner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cairns, David A., Charlotte Pawlyn, Eugene B. Ferris, et al.. (2025). Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling. Blood. 146(22). 2670–2680.

Jenner, Matthew, et al.. (2025). Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline. British Journal of Haematology. 207(6). 2322–2354.

Landgren, Ola, Ajai Chari, Yaël C. Cohen, et al.. (2024). Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS. Blood. 145(15). 1658–1669. 1 indexed citations

Kaiser, Martin, Andrew Hall, Amy Holroyd, et al.. (2024). Extended Intensified Consolidation and Maintenance Improve Ultra High-Risk Multiple Myeloma Patient Outcome - Long-Term Follow-up of the Ukmra Optimum/Muknine Trial. Blood. 144(Supplement 1). 3354–3354.

Jackson, Graham, Charlotte Pawlyn, Faith E. Davies, et al.. (2024). MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation. Blood. 144(Supplement 1). 3375–3375.

Kaiser, Martin, Guy Pratt, Ceri Bygrave, et al.. (2024). Diagnosis and initial treatment of transplant‐eligible high‐risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. British Journal of Haematology. 205(3). 833–839. 3 indexed citations

Kaiser, Martin, Andrew Hall, Katrina Walker, et al.. (2023). Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. Journal of Clinical Oncology. 41(23). 3945–3955. 54 indexed citations

Faustini, Sian, Andrew Hall, Sarah Brown, et al.. (2023). Immune responses to COVID‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. British Journal of Haematology. 201(5). 845–850. 3 indexed citations

Jones, John R, David A. Cairns, Charlotte Pawlyn, et al.. (2023). Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. EClinicalMedicine. 62. 102099–102099. 9 indexed citations

10.

Cairns, David A., Amy Holroyd, Charlotte Pawlyn, et al.. (2022). Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood. 141(14). 1666–1674. 21 indexed citations

11.

Tute, Ruth M. de, Charlotte Pawlyn, David A. Cairns, et al.. (2022). Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology. 40(25). 2889–2900. 40 indexed citations

12.

Jenner, Matthew, Charlotte Pawlyn, Faith E. Davies, et al.. (2022). The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. British Journal of Haematology. 201(2). 267–279. 11 indexed citations

13.

Brown, Sarah, Samantha Hinsley, Louise Flanagan, et al.. (2021). MUK nine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. BMJ Open. 11(3). e046225–e046225. 17 indexed citations

14.

Pawlyn, Charlotte, Martin Kaiser, David A. Cairns, et al.. (2017). Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial. Blood. 130. 3040–3040. 2 indexed citations

15.

Sherborne, Amy L., Vallari Shah, Sidra Ellis, et al.. (2017). Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. Blood. 130. 1767–1767. 2 indexed citations

16.

McCann, Katy J., Lindsey Chudley, Ann Mander, et al.. (2015). Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. Cancer Immunology Immunotherapy. 64(8). 1021–1032. 25 indexed citations

17.

Dickens, Nicholas J., Brian A. Walker, Paola Leone, et al.. (2010). Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome. Clinical Cancer Research. 16(6). 1856–1864. 85 indexed citations

18.

Schey, Stephen, Gareth J. Morgan, Karthik Ramasamy, et al.. (2010). The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology. 150(3). 326–333. 47 indexed citations

19.

Walker, Brian A., Matthew Jenner, Nicholas J. Dickens, et al.. (2008). MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica. 94(1). 78–86. 95 indexed citations

20.

Davies, Faith E., Ping Wu, Matthew Jenner, et al.. (2008). Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT‐PACE. European Journal Of Haematology. 81(6). 432–436. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact